Lactate-induced lactylation and cardiometabolic diseases: From epigenetic regulation to therapeutics

Jie Lin; Jun Ren

doi:10.1016/j.bbadis.2024.167247

Lactate-induced lactylation and cardiometabolic diseases: From epigenetic regulation to therapeutics

Biochim Biophys Acta Mol Basis Dis. 2024 May 16;1870(6):167247. doi: 10.1016/j.bbadis.2024.167247. Online ahead of print.

Authors

Jie Lin¹, Jun Ren²

Affiliations

¹ Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, 200032, China; Shanhai Institude of Cardiovascular Diseases, Shanghai, 200032, China; National Clinical Research Center for Interventional Medicine, Shanghai, 200032, China.
² Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, 200032, China; Shanhai Institude of Cardiovascular Diseases, Shanghai, 200032, China; National Clinical Research Center for Interventional Medicine, Shanghai, 200032, China. Electronic address: ren.jun@zs-hospital.sh.cn.

PMID: 38762059
DOI: 10.1016/j.bbadis.2024.167247

Abstract

Cardiometabolic diseases (CMDs) denote a cadre of chronic and devastating cardiovascular anomalies routed from metabolic derangements including obesity, type 2 diabetes mellitus, and hypertension. Recent studies have demonstrated the association between histone lactylation, a unique form of post-translational modification, and pathogenesis of CMDs, apparently through epigenetic mechanisms. Lactylation has been indicated to regulate key aspects of metabolism, inflammation, and cardiovascular function in the realm of CMDs in a cellular and tissue-specific manner. A better understanding of the molecular, cellular and physiological domains of lactylation in the etiology of CMDs is expected to offer new insights into etiopathogenesis, hazardous factor control and therapeutic development for these challenging ailments.

Keywords: Cardiovascular; Lactylation; Metabolic diseases; Post-translational modifications.

Publication types

Review